Heather D. Turner - 10 Sep 2025 Form 4 Insider Report for LB PHARMACEUTICALS INC

Role
Chief Executive Officer, Director
Signature
/s/ Marc Panoff, Attorney-in-Fact
Issuer symbol
LBRX on Nasdaq
Transactions as of
10 Sep 2025
Net transactions value
$0
Form type
4
Filing time
12 Sep 2025, 18:25:06 UTC
Previous filing
12 Jun 2025
Next filing
02 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Turner Heather D Chief Executive Officer, Director C/O LB PHARMACEUTICALS INC, ONE PENNSYLVANIA PLAZA, SUITE 1025, NEW YORK /s/ Marc Panoff, Attorney-in-Fact 12 Sep 2025 0001403571

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LBRX Employee Stock Option (Right to Buy) Disposed to Issuer -175,706 -100% 0 10 Sep 2025 Common Stock 175,706 $41.84 Direct F1, F2
transaction LBRX Employee Stock Option (Right to Buy) Award +175,706 175,706 10 Sep 2025 Common Stock 175,706 $15.00 Direct F1, F2
transaction LBRX Employee Stock Option (Right to Buy) Disposed to Issuer -7,857 -100% 0 10 Sep 2025 Common Stock 7,857 $41.84 Direct F1, F2
transaction LBRX Employee Stock Option (Right to Buy) Award +7,857 7,857 10 Sep 2025 Common Stock 7,857 $15.00 Direct F1, F2
transaction LBRX Employee Stock Option (Right to Buy) Award $0 +971,828 $0.000000 971,828 10 Sep 2025 Common Stock 971,828 $15.00 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One fourth (1/4) of the shares subject to the option award shall vest on November 18, 2025 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
F2 The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect.
F3 One fourth (1/4) of the shares subject to the option award shall vest on September 10, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.